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Authors’ response
We would like to thank Wójcik et al. [1] for 
their valuable comments to our paper [2] which 
inspired us to further discussion. In our cohort, 
we observed an important discrepancy between 
electrophysiological and clinical efficacy. The first 
one seems to be very important because it makes 
our patients healthy according to World Health 
Organization definition of health. The second 
definition is concordant with electrophysiological 
guidelines [3], however, in the majority of these 
patients, atrial fibrillation (AF) episodes are no 
longer symptomatic and should be included as 
a risk factor for stroke. That is why the redo pro-
cedures were not frequent and the analysis of the 
pattern of reconnections in pulmonary veins (PV) 
has not been not performed so far. We agree that 
the most likely cause of recurrence of paroxysmal 
AF is reconnection in the PV ostia and that in 
patients with persistent AF the problem is more 
sophisticated. Thus, the results in persistent AF 
were worse.
Our center has so far performed circa 1,500 
ablations of AF, including other new single shot 
technologies [4, 5]. We are trying to determine 
the optimal choice of technology for the individual 
patient. Pulmonary vein ablation catheter (PVAC) 
and nMarq catheters seem to be good choices for 
patients who are not optimal for cryoballoon abla-
tion (e.g. allergy to contrast, renal insufficiency, 
thyroid diseases, atypical anatomy).
The analysis of anatomical factors was perfor-
med and presented in our paper. There is a univa-
riate analysis of factors that influence the efficacy 
of the method. Common pulmonary trunk was not 
a risk factor for worse prognosis of PV isolation. 
However, in our general population common pul-
monary trunk decreased the success rate of the 
ablation procedure [6].
Our complication rate was smaller than in the 
Worldwide Survey [7] and the US-study [8]. To 
increase the safety of PVAC we are trying to use 
guidelines from ERACE trial in which the amount 
of silent cerebral ischemia was similar to other 
methods used in pulmonary vein isolation.
We agree that PVAC ablation should be rat-
her reserved for selected population, including 
PV-trigger-dependent AF and performed by an 
experienced operator. Nowadays, we do not use it 
in patients with persistent AF.
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